ICON PLC is a leading global provider of clinical research services to pharmaceutical, biotechnology, and medical device industries. ICON PLC is guided by a set of core values and corporate philosophy that focuses on innovation, integrity, collaboration, and excellence. The company's commitment to delivering high-quality research and development solutions, while maintaining ethical practices, has made it a trusted partner for successful clinical trials. With its dedication to advancing healthcare and improving patient outcomes, ICON PLC continues to be a respected and influential player in the industry.

ICON PLC is primarily present in various countries and regions globally. With a strong international presence, the company operates in multiple key markets, including the United States, United Kingdom, Ireland, Europe, Asia-Pacific, and the Middle East. This global footprint enables ICON PLC to cater to clients worldwide and deliver its comprehensive range of professional services.

ICON PLC, a leading clinical research organization, has achieved significant milestones throughout its history. The company's accomplishments include becoming a key player in the development and execution of clinical trials worldwide. ICON PLC has successfully expanded its global footprint, delivering exceptional services in over 100 countries. With a strong focus on innovation and technology, the company has pioneered industry-leading solutions to enhance clinical trial processes and improve patient outcomes. ICON PLC's dedication to excellence has resulted in numerous accolades and recognition within the pharmaceutical and biotechnology industries. By consistently delivering high-quality results and establishing strategic partnerships, ICON PLC has solidified its reputation as a trusted and influential player in the field of clinical research.

ICON PLC, also known as ICON, is a well-established global provider of clinical research and development services to the pharmaceutical, biotechnology, and medical device industries. Founded in 1990 in Dublin, Ireland, ICON has since expanded its operations worldwide, with offices in over 40 countries. The company offers various services, including clinical trial management, data management and analysis, regulatory support, and post-market surveillance. With a strong focus on innovation and expertise, ICON has successfully collaborated with numerous healthcare organizations to accelerate the development of innovative therapies and improve patient outcomes. Due to its vast experience and industry reputation, ICON PLC continues to be a trusted partner in advancing healthcare solutions globally.

The main competitors of ICON PLC in the market include other Contract Research Organizations (CROs) such as Covance Inc., QuintilesIMS Holdings Inc., and PAREXEL International Corporation. These companies provide similar services and solutions in the clinical research and development industry, offering competition to ICON PLC's global presence and expertise.

ICON PLC is primarily active in the pharmaceutical, biotechnology, and medical device industries.

The business model of ICON PLC is centered around providing clinical research services to pharmaceutical, biotechnology, and medical device companies. ICON offers a range of services including clinical trial management, data collection and analysis, regulatory consulting, and patient recruitment. They help their clients with the development and commercialization of new drugs and treatments by conducting clinical trials and ensuring regulatory compliance. With a strong focus on innovation and expertise in the field, ICON PLC has established itself as a trusted partner for the life sciences industry.

ICON의 P/E 비율은 9.65입니다.

ICON의 P/S 비율은 1.37입니다.

ICON에 대한 AlleAktien 품질 점수는 7/10입니다.

예상되는 ICON 매출은 8.13 조. USD입니다.

예상되는 ICON 이익은 1.15 조. USD입니다.

ICON plc is a leading global company in the field of clinical research and development of pharmaceuticals. It offers a wide range of services in clinical trials, consulting, strategy development, laboratory analysis, and data management. The company is divided into three main business areas: clinical development services, laboratory analysis, and data management. It works closely with its customers and partners to develop groundbreaking medications and treatments. ICON is known for its Enterprise Laboratory Information Management System (LIMS) and EDC solutions. It has a robust business model and is well-positioned for future growth.

ICON은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

ICON의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

ICON의 ISIN은 IE0005711209입니다.

ICON의 WKN은 932242입니다.

ICON의 티커는 ICLR입니다.

지난 12개월 동안 ICON은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 ICON은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

ICON의 현재 배당 수익률은 입니다.

ICON은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

ICON은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

ICON은 '건강' 섹터에 속합니다.

ICON의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2024년에 ICON는 0 USD를 배당금으로 지급했습니다.

ICON의 배당금은 USD에 지급됩니다.